Pneumonia Therapeutics Market Report 2026

Pneumonia Therapeutics Market Overview

• Pneumonia Therapeutics market size has reached to $11.46 billion in 2025 • Expected to grow to $18.83 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: Rising Pneumonia Cases Fuel Demand For Advanced Treatments • Market Trend: Innovative Approaches To Combating Antibiotic Resistance In Pneumonia Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pneumonia Therapeutics Market?

Pneumonia therapeutics refer to a range of treatments and medications used to manage and treat pneumonia, a lung infection that are caused by bacteria, viruses, or fungi. These therapeutics target the underlying pathogens, reduce inflammation, and improve respiratory functions. Treatments include antibiotics for bacterial pneumonia, antiviral medications for viral pneumonia, and antifungal agents for fungal infections. The main products of pneumonia therapeutics are drugs, vaccines, and oxygen therapy. Drugs for pneumonia therapeutics address the root cause (bacteria, viruses, or fungi) and alleviate symptoms through antibiotics, antivirals, antifungals, and supportive treatments such as oxygen therapy. The infections treated comprise hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and ventilator-associated pneumonia (VAP). The routes of administration include oral, parenteral, and other methods and are used by end users such as hospitals, home care, specialty clinics, and others.

What Is The Pneumonia Therapeutics Market Growth Forecast?

The pneumonia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $18.83 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing development of novel antibiotics and antivirals, rising adoption of rapid diagnostic testing, growing focus on antimicrobial resistance management, expansion of homecare pneumonia treatment models, increasing investment in vaccine-based prevention strategies. Major trends in the forecast period include increasing adoption of targeted antimicrobial therapies, rising use of combination drug regimens, growing focus on early pathogen identification, expansion of home-based oxygen therapy solutions, enhanced emphasis on hospital infection control protocols.

Global Pneumonia Therapeutics Market Segmentation

1) By Product: Drugs, Vaccine, Oxygen Therapy 2) By Infection: Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Ventilator-Associated Pneumonia (VAP) 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By End Use: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Drugs: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids 2) By Vaccine: Pneumococcal Vaccines, Haemophilus Influenzae Type B (Hib) Vaccines, Influenza Vaccines 3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC), Non-Invasive Ventilation (NIV), Mechanical Ventilation

What Is The Driver Of The Pneumonia Therapeutics Market?

The rising prevalence of pneumonia is expected to drive the growth of the pneumonia therapeutics market going forward. Pneumonia refers to a lung infection that inflames the air sacs, often causing symptoms such as cough, fever, and difficulty breathing. Increasing pneumonia cases can be attributed to factors such as aging populations, air pollution, smoking, weakened immune systems, antimicrobial resistance, and the spread of respiratory infections like COVID-19 or influenza. Pneumonia therapeutics help to combat the infection's cause, such as bacteria, viruses, or fungi, using targeted medications while supporting recovery through oxygen therapy, anti-inflammatory drugs, and symptom management. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based government agency, globally, pneumonia affects about 120 million people annually, causing approximately 1.3 million deaths. Nearly 80% of pediatric pneumonia deaths occur in children under 2 in developing countries. Therefore, the increasing prevalence of pneumonia is driving the growth of the pneumonia therapeutics industry.

Key Players In The Global Pneumonia Therapeutics Market

Major companies operating in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc.

Global Pneumonia Therapeutics Market Trends and Insights

Major companies operating in the pneumonia therapeutics market focus on developing innovative drug formulations and treatment methods such as antibiotic drugs to address antibiotic resistance and improve patient outcomes. An antibiotic drug refers to a type of medication specifically designed to treat bacterial infections. For instance, in June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, collaborated with Cipla Limited, an India-based pharmaceutical company, to introduce cefepime-enmetazobactam. This antibiotic combination is used to treat complex infections, including UTIs and pneumonia, particularly those resistant to other medications. It helps combat bacterial resistance, ensuring effective treatment while minimizing the need for stronger antibiotics.

What Are Latest Mergers And Acquisitions In The Pneumonia Therapeutics Market?

In June 2023, Novo Holdings and Gurnet Point Capital, US-based investment firms, acquired Paratek Pharmaceuticals, Inc. for approximately US$462 million. Through this acquisition, the firms gained ownership of Paratek’s antibiotic portfolio, including Nuzyra (omadacycline), an FDA-approved treatment for community-acquired bacterial pneumonia (CABP), thereby strengthening their presence in the pneumonia therapeutics market. Paratek Pharmaceuticals, Inc. is a US-based biopharmaceutical company that provides antibiotic therapies, notably Nuzyra, available in both oral and intravenous formulations for the treatment of bacterial pneumonia.

Regional Outlook

North America was the largest region in the pneumonia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pneumonia Therapeutics Market?

The pneumonia therapeutics market consists of revenues earned by entities by providing services such as chest X-rays, blood tests, sputum culture, oxygen supplementation, mechanical ventilation, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pneumonia therapeutics market also includes sales of pneumococcal vaccines, antibiotics, nebulizers, and inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pneumonia Therapeutics Market Report 2026?

The pneumonia therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pneumonia therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.